BRCA1, BRCA2, PALB2 and CDKN2A mutations in familial pancreatic cancer: a PACGENE study

BRCA1andBRCA2germline mutations are frequently demonstrated in both high-risk pancreatic cancer screening and pancreatic cancer cohorts

(2014) Aimee L. Lucas et al.   CANCER

Projecting Cancer Incidence and Deaths to 2030: The Unexpected Burden of Thyroid, Liver, and Pancreas Cancers in the United States

(2014) L. Rahib et al.   CANCER RESEARCH

The Early Detection of Pancreatic Cancer: What Will It Take to Diagnose and Treat Curable Pancreatic Neoplasia?

(2014) A. M. Lennon et al.   CANCER RESEARCH

High Prevalence of BRCA1 and BRCA2 Germline Mutations with Loss of Heterozygosity in a Series of Resected Pancreatic Adenocarcinoma and Other Neoplastic Lesions

(2013) A. L. Lucas et al.   CLINICAL CANCER RESEARCH

The incidence of pancreatic cancer in BRCA1 and BRCA2 mutation carriers

(2012) J Iqbal et al.   BRITISH JOURNAL OF CANCER

Clinical significance of large rearrangements inBRCA1andBRCA2

(2012) Thaddeus Judkins et al.   CANCER

International Cancer of the Pancreas Screening (CAPS) Consortium summit on the management of patients with increased risk for familial pancreatic cancer

(2012) Marcia Irene Canto et al.   GUT

Indication forCDKN2A-mutation analysis in familial pancreatic cancer families without melanomas

(2012) Femme Harinck et al.   JOURNAL OF MEDICAL GENETICS

Prevalence ofBRCA1andBRCA2mutations in Ashkenazi Jewish families with breast and pancreatic cancer

(2011) Zsofia K. Stadler et al.   CANCER

Routine testing for PALB2 mutations in familial pancreatic cancer families and breast cancer families with pancreatic cancer is not indicated

(2011) Femme Harinck et al.   EUROPEAN JOURNAL OF HUMAN GENETICS

Genetic susceptibility to pancreatic cancer

(2011) Alison P. Klein   MOLECULAR CARCINOGENESIS

An Emerging Entity: Pancreatic Adenocarcinoma Associated with a Known BRCA Mutation: Clinical Descriptors, Treatment Implications, and Future Directions

(2011) M. A. Lowery et al.   ONCOLOGIST

Absence of germline BRCA1 mutations in familial pancreatic cancer patients

(2010) Jennifer E. Axilbund et al.   CANCER BIOLOGY & THERAPY

Pancreatic Cancer Screening in a Prospective Cohort of High-Risk Patients: A Comprehensive Strategy of Imaging and Genetics

(2010) E. C. Verna et al.   CLINICAL CANCER RESEARCH

PALB2 mutations in European familial pancreatic cancer families

(2010) EP Slater et al.   CLINICAL GENETICS

Prevalence of CDKN2A mutations in pancreatic cancer patients: implications for genetic counseling

(2010) Robert R McWilliams et al.   EUROPEAN JOURNAL OF HUMAN GENETICS

Therapeutic Potential of Poly(ADP-ribose) Polymerase Inhibitor AG014699 in Human Cancers With Mutated or Methylated BRCA1 or BRCA2

(2010) Yvette Drew et al.   JNCI-Journal of the National Cancer Institute

Polymorphic Variants in Hereditary Pancreatic Cancer Genes Are Not Associated with Pancreatic Cancer Risk

(2009) R. R. McWilliams et al.   CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION

Five years of prospective screening of high-risk individuals from families with familial pancreatic cancer

(2009) P Langer et al.   GUT

Exomic Sequencing Identifies PALB2 as a Pancreatic Cancer Susceptibility Gene

(2009) S. Jones et al.   SCIENCE

ACMG recommendations for standards for interpretation and reporting of sequence variations: Revisions 2007

(2008) C Sue Richards et al.   GENETICS IN MEDICINE

Germline BRCA1 mutations predispose to pancreatic adenocarcinoma

(2008) Wigdan Al-Sukhni et al.   HUMAN GENETICS